SMMT
Summit Therapeutics Inc. Common Stock
Nasdaq · usd
Summit Therapeutics Inc. Common Stock (SMMT) trades at $10.67 (-9.73%) as of 7:59:30 PM EST on Nov 17, 2026, -31.47% over the past month. Market cap is $9.45B, with 9.4 days to cover in short interest.
Stock performance
How Summit Therapeutics Inc. Common Stock (SMMT) stock has performed from one day to one year, with its 52-week range.
- 1D
- -9.73%
- 1W
- -40.16%
- 1M
- -31.47%
- YTD
- -38.99%
- 1Y
- -36.53%
- 52-wk range
- $10.53 – $29.23
Key statistics
Today's trading snapshot for SMMT: day range, open, previous close, volume and market cap.
- Day range
- $10.53 – $11.91
- Open
- $11.70
- Prev close
- $11.82
- Volume
- 13.17M
- Market cap
- $9.45B
- Shares out
- 799.76M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Summit Therapeutics Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 16.74
- P/FCF
- —
- ROE
- -147.5%
- ROA
- -120.2%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 16, 2026
8-K filings
Material corporate events Summit Therapeutics Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 4, 2026
On November 4, 2026, Summit Therapeutics Inc. (the "Company") issued a press release announcing its financial results and operational progress for the third quarter ended September 30, 2026.
- Private placementSep 29, 2026
On September 28, 2026, Summit Therapeutics Inc. entered into a securities purchase agreement with AstraZeneca Holdings B.V. for the issuance and sale of 108,955.3686 shares of newly designated Class A Convertible Preferred Stock at a purchase price of $18,356.14 per share, for aggregate gross proceeds of $2.0 billion. The Preferred Shares and any shares issuable upon conversion will be issued in reliance on the exemption from registration under Section 4(a)(2) and/or Rule 506 of Regulation D.
- Clinical trial resultsSep 15, 2026
On September 15, 2026, Summit Therapeutics Inc. issued a press release announcing that updated overall survival results from the global Phase III HARMONi clinical trial were presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer (WCLC 2026).
- Clinical trial resultsSep 3, 2026
On September 2, 2026, Summit Therapeutics Inc. issued a press release noting that its partner, Akeso Inc., announced positive overall survival ("OS") results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer whose tumors have positive PD-L1 expression. In this preplanned analysis of OS, a secondary endpoint in HARMONi-2, Akeso reported that ivonescimab monotherapy demonstrated a statistically significant improvement compared to pembrolizumab monotherapy.
- Clinical trial resultsAug 26, 2026
Akeso reported that, at a pre-specified interim analysis, the ivonescimab-based regimen achieved statistically significant and clinically meaningful superiority in the primary endpoint of overall survival compared to the durvalumab-based regimen. The study also met the key secondary endpoints of progression-free survival and objective response rate.
SMMT short interest
How heavily SMMT is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 9.4
- Short interest
- 42.26M
- Avg volume
- 4.5M
As of · reported to FINRA twice monthly.
SMMT news
The latest news and headlines about Summit Therapeutics Inc. Common Stock (SMMT).
- Revolution Medicines Wins EU Nod for Rasonque in Pancreatic CancerpositiveZacks Investment Research· Nov 17, 2026
- Summit Stock Falls on FDA Rejection for Lung Cancer DrugnegativeZacks Investment Research· Nov 16, 2026
- Breakfast News: Summit’s FDA Setback Isn’t the EndnegativeThe Motley Fool· Nov 16, 2026
- Wall Street Analysts See a 62.33% Upside in Summit Therapeutics (SMMT): Can the Stock Really Move This High?positiveZacks Investment Research· Nov 10, 2026
- SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in FocuspositiveZacks Investment Research· Nov 5, 2026
Frequently asked questions
What is the Summit Therapeutics Inc. Common Stock (SMMT) stock price today?
Summit Therapeutics Inc. Common Stock (SMMT) is trading at $10.67 (-9.73% on the day) as of 7:59:30 PM EST on Nov 17, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Summit Therapeutics Inc. Common Stock?
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases.
What is the short interest in SMMT?
As of Oct 30, 2026, SMMT has 42.26M shares short and 9.4 days to cover.
What exchange is SMMT listed on?
Summit Therapeutics Inc. Common Stock (SMMT) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of SMMT with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a SMMT analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.